Market Overview

US Stock Futures Gain Ahead Of Factory Orders Data

US Stock Futures Gain Ahead Of Factory Orders Data

Pre-open movers

US stock futures traded higher in early pre-market trade. Data on motor vehicle sales for January will be released today. Data on factory orders for will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average jumped 54 points to 17,353.00, while the Standard & Poor's 500 index futures rose 6.90 points to 2,024.00. Futures for the Nasdaq 100 index gained 10 points to 4,195.50.

A Peek Into Global Markets

European markets were higher today, with the Spanish Ibex Index rising 1.27%, STOXX Europe 600 Index gaining 1.26% and German DAX 30 index rising 1.18%. French CAC 40 Index gained 1.29% and London's FTSE 100 Index rose 1.20%.

In Asian markets, Japan's Nikkei Stock Average fell 1.27%, Hong Kong's Hang Seng Index rose 0.29%, China's Shanghai Composite Index jumped 2.45% and India's BSE Sensex tumbled 0.42%. China posted a current account surplus of $61.1 billion for the fourth quarter, versus a revised current-account surplus of $72.2 billion in the third quarter.

Broker Recommendation
Analysts at Deutsche Bank upgraded Sysco Corporation (NYSE: SYY) from Hold to Buy. The price target for Sysco has been raised from $40 to $50.

Sysco's shares closed at $38.43 yesterday.

Breaking news

  • Aetna Inc. (NYSE: AET) reported in-line earnings for the fourth quarter and raised its full-year forecast. To read the full news, click here.
  • HealthSouth Corporation (NYSE: HLS) today announced it has entered into an agreement to purchase Cardinal Hill Rehabilitation Hospital in Lexington, Kentucky, from the Kentucky Easter Seal Society, Inc. To read the full news, click here.
  • SS&C Technologies Holdings, Inc. (NASDAQ: SSNC) and Advent Software, Inc. (NASDAQ: ADVS) announced that the companies have entered into a definitive agreement wherein SS&C will acquire Advent. To read the full news, click here.
  • Auspex Pharmaceuticals (NASDAQ: ASPX) today announced that it has completed target enrollment in its pivotal clinical trial of SD-809 for the potential treatment of tardive dyskinesia (TD), called ARM-TD. To read the full news, click here.

Related Articles (AET + SYY)

View Comments and Join the Discussion!

Posted-In: Deutsche Bank US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets